Set up in 1973, family-owned Bronco Wine sells a range of brands, including domestic names Rosenblum Cellars and Cedar Brook, and imported brands Chateau de la Roche and Tierra Brisa. According to ...

Here's why La Roche-Posay is pulling its Effaclar Duo Acne Spot Treatment from retail shelves. La Roche-Posay is a brand under the L'Oreal Group umbrella. A La Roche-Posay spokesperson confirmed ...

Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise Research Campus in Allston that could employ hundreds. The Roche ...

The products are being recalled by the FDA for possible "benzene contamination." Acne creams from retailers including Walgreens, La Roche-Posay and Proactiv have been voluntarily recalled due to ...

Today, I'm checking out a stunning home on wheels that has the best of both worlds. Meet Brisa, a tiny home on wheels based on the Fiat Ducato L2H2. It's the work of Dora Camper Studio ...

LONDON — Looking to expand its obesity offerings, Roche on Wednesday said it had partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion in upfront cash.

ZURICH (Reuters) -Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in ...

We explore the history of global pharmaceutical group Hoffmann-La Roche from where it first began, to its core structure and its focus for the future in personalised medicine. Roche was found in ...

Os lucros da Brisa cresceram quase 18% em 2024 em relação ao período homólogo A Brisa Concessão Rodoviária (BCR) registou, no ano passado, lucros de 325,9 milhões de euros, um aumento de 17 ...

Roivant, the source of Roche’s TL1A prospect, reported a 21% delta compared to placebo after 12 weeks. Prometheus Biosciences, which Merck acquired, saw a 31% placebo-adjusted rate of endoscopic ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).